22320-10-1

Basic information

• Product Name: 4-Hydroxybenzenebutyric acid methyl ester
• Synonyms: 4-Hydroxybenzenebutyric acid methyl ester;p-Hydroxybenzenebutanoic acid methyl ester;Benzenebutanoic acid, 4-hydroxy-, Methyl ester;Methyl 4-(4-hydroxyphenyl)butanoate
• CAS NO: 22320-10-1
• Molecular Formula: C₁₁H₁₄O₃
• Molecular Weight: 194.23
• Mol File: 22320-10-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 321.4°C at 760 mmHg
• Flash Point: 136°C
• Appearance: /
• Density: 1.118g/cm³
• Vapor Pressure: 0.000159mmHg at 25°C
• Refractive Index: 1.526
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 4-Hydroxybenzenebutyric acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Hydroxybenzenebutyric acid methyl ester(22320-10-1)
• EPA Substance Registry System: 4-Hydroxybenzenebutyric acid methyl ester(22320-10-1)

Safety Data

• Hazardous Substances Data: 22320-10-1(Hazardous Substances Data)

Usage

Uses

4-?Hydroxy-?benzenebutanoic Acid Methyl Ester is an intermediate in synthesizing Arbutamine (A766300). It is a cardiac stimulant. Arbutamine stimulates adrenergic receptors.

InChI:InChI=1/C11H14O3/c1-14-11(13)4-2-3-9-5-7-10(12)8-6-9/h5-8,12H,2-4H2,1H3

Upstream product

• 67-56-1 methanol 
• 7021-11-6 4-(4-hydroxyphenyl)butanoic acid 
• 4521-28-2 4-(4-Methoxyphenyl)butyric acid 
• 74-88-4 methyl iodide 
• 20637-08-5 4-(4-methoxyphenyl)butyric acid methyl ester 

Downstream Products

• 18093-69-1 4--buttersaeure 
• 18093-68-0 4--buttersaeure 
• 344348-83-0 4-(4-Oxiranylmethoxy-phenyl)-butyric acid methyl ester 
• 153939-52-7 4-{4-[2-(Benzooxazol-2-yl-methyl-amino)-ethoxy]-phenyl}-butyric acid methyl ester 
• 872674-81-2 methyl 4-[4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethoxy]phenyl]butanoate 
• 912338-82-0 methyl 4-{4'-[4''-(tert-butyldimethylsilanyloxy)butoxy]phenyl}butanoate 
• 868850-05-9 4-{4-[(3-fluorobenzyl)oxy]phenyl}butanoic acid 

Relevant articles and documents

Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is a severe liver disease causing serious liver complications, including nonalcoholic steatohepatitis (NASH). Nuclear receptor PPARα (peroxisome proliferator-activated receptor α) has drawn special attention recently as a potential developmental drug target to treat type-2 diabetes and related diseases due to its unique functions in regulating lipid metabolism, promoting triglyceride oxidation, and suppressing hepatic inflammation, raising interest in PPARα agonists as potential therapies for NAFLD. However, how PPARα coordinates potential treatment of NAFLD and NASH between various metabolic pathways is still obscure. Here, we show that the DY series of novel selective PPARα modulators activate PPARα by up-regulating PPARα target genes directly involved in NAFLD and NASH. The design, synthesis, docking studies, and in vitro and in vivo evaluation of the novel DY series of PPARα agonists are described.

G-PROTEIN-CONJUGATED RECEPTOR AGONIST

Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic agent for a gastrointestinal disease, a therapeutic agent for a neuropathy, a therapeutic agent for a mental disorder, a therapeutic agent for a pulmonary disease, a therapeutic agent for a pituitary hormone secretion disorder or a lipid flavoring/seasoning agent. The aralkyl carboxylic acid compound is represented by the general formula (I). (I) wherein the ring Q represents a pyridyl or the like; R1 represents a C1-6 alkyl group or the like; R2 represents a hydrogen atom, a C1-4 alkyl group or a C1-4 alkoxy group; m and n independently represent an integer of 1 to 5; and X represents an oxygen atom, a sulfur atom or - NR3- [wherein R3 represents a hydrogen atom or a C1-4 alkyl group].

CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER

The invention provides novel compounds of formula (I), wherein: R1 is a radical derived from one of the known ring systems; R2 is a phenyl radical optionally substituted; Xn represents a birradical selected from the group consisting of: -(CH2)1-4-, (C2-C4)-alkenyl, (C2-C4)alkynyl, -S-(CH2)1-3-#, and -(CH2)1-3-O-#; wherein the symbol # indicates the position at which Xn is attached to R1; Yn is a birradical selected from the group consisting of: -(CH2)2-4-, -S-(CH2)1-3#, and -O-(CH2)1-3-#,; where in the symbol # indicates the position at which Yn is attached to R2; and R3 is a radical selected from the group consisting of: -OR4. The compounds of formula (I) are useful in the treatment of cancer